fbpx

AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials

by | Nov 11, 2024 | AlphaTack Intel

  • Company acquired drug as part of $8.7 billion Cerevel purchase
  • Bristol jumps most in 18 years after competitor’s setback